Breast Cancer Metastases Based on Molecular Subtypes at RSUD Dr. H. Abdul Moeloek Lampung
DOI:
https://doi.org/10.36408/mhjcm.v10i3.904Keywords:
breast cancer, molecular subtypes, metastasesAbstract
BACKGROUND:Breast cancer is the most common cancer in Indonesia and is a leading cause of cancer-related deaths in the country. Metastases are responsible for most deaths among breast cancer patients. Breast cancer is typically classified into four subtypes based on immunohistochemistry: luminal A, luminal B, HER2+, and TNBC.
OBJECTIVE:To determine the association between the metastatic pattern of breast cancer and their molecular subtypes at RSUD Dr. H. Abdul Moeloek Lampung.
METHOD:This study was an observational analytic study with a cross-sectional design. The sample comprised 81 individuals who had suffered from breast cancer and were recorded in the medical records section of RSUD Dr. H. Abdul Moeloek Lampung between 2013 – 2021 and met the inclusion and exclusion criteria. The association between breast cancer subtypes and the incidence and metastase sites were tested using the Chi-Square test.
RESULT:This study found a significant association between breast cancer subtypes and the incidence of metastases (p <0.05). The TNBC subtype had a more frequent rate of metastases (34.5%) than the other subtypes (31% luminal B, 20.7% luminal A, and HER2+ 13.8%). The study also revealed a relationship between ER status and the incidence of metastases (p < 0.05). The luminal A subtype tends to metastasize to the liver, luminal B tends to metastasize to the bone, HER2+ tends to metastasize to the lung and liver, and TNBC tends to metastasize to the lung. However, no significant association was found between breast cancer subtypes and metastatic sites.
CONCLUSION:There was a significant association between breast cancer subtypes and the incidence of metastases, but not with the metastatic sites.
Downloads
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal DMV, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–49. doi:3322/caac.21660
2. Pangribowo S. 2019. Cancer Burden in Indonesia, Indonesian Ministry of Health Data and Information Center.
3. Ministry of Health of the Republic of Indonesia. 2022. Most Common Breast Cancer in Indonesia, Ministry of Health Targets Equalization of Health Services [Internet]. Available from:https://www.kemkes.go.id/article/view/22020400002/kanker-payudara-paling-besar-di-indonesia-kemenkes-targetkan-pemerataan- jasa-kesehatan.html
4. 2022. Metastatic Breast Cancer StatisticsNo Title. Metastatic Breast Cancer Research, Support and Awareness [Internet]. Available forms:https://www.metavivor.org/mbc-prep/metastatic-breast-cancer-statistics
5. American Cancer Society. 2019. Breast Cancer Facts & Figures 2019-2020, Atlanta: American Cancer Society.
6. Van Uden DJP, Van Maaren MC, Strobbe LJA, Bult P, Van Der Hoeven JJ, et al. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. Breast Cancer Res. 2019;21(1):1–9. doi:1186/s13058-019-1201-5
7. Chikarmane SA, Tirumani SH, Howard SA, Jagannathan JP, Dipiro PJ. Metastatic patterns of breast cancer subtypes: What radiologists should know in the era of personalized cancer medicine. Clin Radiol. 2015;70(1):1–10. doi:1016/j.crad.2014.08.015
8. Yang H, Wang R, Zeng F, Zhao J, Peng S, et al. Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the surveillance, epidemiology and end results database. Oncology Letters. 2020;20(4):1–3. doi:3892/ol.2020.11948
9. Helmi AF, Khambri D, Rustam R. The Relationship of Breast Cancer Subtypes with the Event of Metastasis in. Biosecientia Medicina: Journal of Biomedicine & Translational Research. 2021;1(1):399–405. doi:32539/bsm.v5i4.410
10. Akrami M, Tahmasebi S, Zangouri V, Hosseini S, Talei A. Metastatic Behavior of Breast Cancer Subtypes. Multidisciplinary Cancer Investigation. 2017;1(1):102. doi:21859/mci-supp-102
11. Gong Y, Liu YR, Ji P, Hu X, Shao ZM. Impact of molecular subtypes on metastatic breast cancer patients: A SEER population-based study. Sci Rep. 2017;7(2):1–10. doi:1038/srep45411
12. Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, et al. Breast cancer subtypes predict the preferential site of distant metastases: A SEER based study. Oncotarget. 2017;8(17):90–6. doi:18632/oncotarget.15856
13. Tagliabue G, Fabiano S, Contiero P, Barigelleti G, Castelli M, Mazzoleni G, et al. Molecular subtypes, metastatic pattern and patient age in breast cancer: An analysis of Italian Network of Cancer Registries (AIRTUM) data. J Clin Med. 2021; 10(24):1-13. doi:3390/jcm10245873
14. Takaltar UV, Advani S. Prognostic indicators in breast cancer. Science Forecast. 2018;1(1):1–3.
15. Guo Y, Arciero CA, Jiang R, Behera M, Peng L, Li X. Different breast cancer subtypes show different metastatic patterns: A study from a large public database. Asian Pac J Cancer Prev. 2020; 21(12):3587-3593. doi:31557/APJCP.2020.21.12.3587.
16. Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, et al. Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat. 2015; 150(3):621-9. doi: 10.1007/s10549-015-3341-3
17. Jamnasi J, Gondhowiardjo S, Djoerban Z, Siregar NC, Poetiray EDC, Tunggono AP. Risk factors for distant metastasis in breast cancer patients. Indonesian Radiotherapy & Oncology. 2016;7(2):55–9. doi:32532/jori.v7i2.46
18. Anwar S, Avanti WS, Nugroho AC, Choridah L, Dwianingsih EK, Harahap WA, et al. Risk factors of distant metastasis after surgery among different breast cancer subtypes: A hospital-based study in Indonesia. World Journal of Surgical Oncology. 2020;18(1):1–16. doi:1186/s12957-020-01893-w
19. Perales GIU, Facio SKS, Dominiguea CNS, Huerta SC, Maldonado GEM, Flores PR, et al. Genetic alterations of triple negative breast cancer (TNBC) in women from northeastern Mexico. Oncol Lett. 2019; 17(3):3581-3588. doi:3892/ol.2019.9984
20. Pillai SKK, Tay A, Nair S, Leong CO. Triple negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clinic Pathol. 2012; 12(18):1-8. doi:1186/1472-6890-12-18
21. Yu T, Di G. Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. Chin J Cancer Res. 2017; 29(3):237-252. doi:21147/j.issn.1000-9604.2017.03.10
22. Wiguna N, Manuaba I. Characteristics of immunohistochemical examination in breast cancer patients at Sanglah General Hospital for the period 2003-2012. Udayana Medika E-Journal. 2014;3(7):1–13.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2023 Indri Windarti, Nurmayeni, Agustyas Tjiptaningrum, Bintang Abadi Siregar, Aditya Kusumaningtyas, Indri Windarti
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
